Which Type of Underlying Disease Facilitates Cytomegalovirus Infection? Comparison of Benign Disease, Hematopoietic Malignancy, and Post-bone-marrow or Renal Transplantation Status by Using the First Standardized Objective PCR Test for Cytomegalovirus Detection.

Motofumi HIYOSHI, Shinichi TAGAWA, Shigemi HASHIMOTO and Noriyuki TATSUMI
Department of Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
(Received : September 4, 1998)
(Accepted : November 12, 1998)

Key words: cytomegalovirus, PCR, bone marrow transplantation, immunocompromised host

Abstract

All immunocompromised hosts, such as infants, the elderly, patients with advanced cancer, and patients being treated with immunosuppressants, etc., are said to be more susceptible to cytomegalovirus (CMV) infection or CMV disease. However, we questioned the validity of this conclusion and attempted to detect CMV viremia in the plasma of subjects by using the AMPLICOR™ CMV test (Roche Diagnostics Systems, Branchburg, NJ), the first standardized PCR kit for CMV infection. One hundred healthy volunteers whose CMV IgG titer was <4 and 100 healthy volunteers whose IgG titer for CMV was ≥4 were studied. None of the subjects in either healthy group was positive for CMV viremia. Patients who were suspected of CMV infection were divided into four groups and tested: [1] 104 patients with benign disease, only one of whom was positive for CMV [2] 99 patients with hematopoietic malignancy who had not undergone bone marrow transplantation and all of whom were negative for CMV infection [3] 120 post-bone-marrow transplantation, 28 of whom were CMV positive, [4] 37 post-renal transplantation patients, 19 of whom were CMV positive. A statistically significant difference in CMV positivity was found by the non-parametric Kruskal-Wallis test (p<0.0001) among the four disease group. CMV infection has been said to occur in all types of immunocompromised patients, however, based on our findings, we conclude that CMV infection tends to occur in post-transplantation status and does not tend to occur in patients with hematopoietic malignancy if they have not undergone transplantation.

Introduction

Since organ transplantation medicine has developed and succeeded recently, CMV infection is now being taken seriously as a complication of post-transplantation status.

The problem is that it has been difficult to diagnose CMV infection accurately and immediately, with the result that treatment for possible CMV infection or CMV disease has been started even when laboratory tests for CMV have not been positive. Conventional laboratory tests for CMV infection consist of direct culture methods, serologic methods, and antigenemia assay using monoclonal antibody, but none has
Which underlying disease facilitates cytomegalovirus infection?

been satisfactory in terms of sensitivity, specificity, and time required until the results are available21−30.

The polymerase chain reaction (PCR) is a very promising technique for hospital laboratory work and is now being utilized to diagnose CMV infection31−38. Thus, at last a standardized objective laboratory test for CMV infection by PCR has become available in clinical medicine39. The performance of the test is satisfactory, and its sensitivity and specificity are reported to be 97.1% and 100%, respectively40.

It has been said that all types of immunocompromised hosts, such as infants, the elderly, patients with advanced cancer, and patients undergoing treatment with immunosuppressants, etc., are susceptible to CMV infection or CMV disease1). We wondered if this was true, but no standardized objective method was available to investigate this question properly. When we were given an opportunity to use the above-mentioned PCR laboratory test, the first standardized objective test for CMV infection, we used it to identify the conditions that facilitate CMV infection in the immunocompromised patients.

Materials and Methods

Study population and sample collection

All specimens were collected after obtaining informed consent. As controls, plasma specimens (EDTA) were collected from 100 healthy volunteers, age 34.1 ± 5.1 years (average (mean ± standard deviation)) who was CMV IgG titer negative (<4) and 100 healthy volunteers, age 33.7 ± 6.7 years, whose IgG titer for CMV was positive (≥4). All of these volunteers had negative for IgM titers for CMV (<4). The serologic CMV antibody studies (both IgG and IgM) were performed by a standard complement fixation method. Of course, the healthy volunteers did not exhibit any symptoms of infectious disease. To compare the four different conditions, plasma specimens were taken from patient when they developed an unexplained fever that persisted for over 7 days and did not respond to antibacterial antibiotic or antifungal antibiotic therapy; i.e., when the patients were suspected of having CMV infection or CMV disease. There were four categories of patients: [1] 104 patients with benign conditions (50, diabetes mellitus; 30, post-cardiovascular surgery; 23, collagen vascular disease; 1, diagnosis not made, but at least, no malignant tumors were detected), [2] 99 patients with hematopoietic malignancy (40, acute leukemia; 35, malignant lymphoma; 10, chronic myelogenous leukemia in blastic crisis; and 14, myelodysplastic syndrome), [3] 120 patients who had undergone bone marrow transplantation (80, acute leukemia in complete remission; 40, chronic myelogenous leukemia in chronic phase), [4] and 37 patients who underwent renal transplantation for chronic glomerulonephritis. Specimens were collected within 120 days of bone marrow or renal transplantation. All specimens from healthy volunteers and patients were stored at −80°C for future CMV detection. All healthy volunteers and patients tested negative for human immunodeficiency virus (HIV).

Polymerase chain reaction for cytomegalovirus

The polymerase chain reaction was performed by using the AMPLICOR® CMV test (Roche Diagnostics Systems, Branchburg, NJ) according to the manufacturer's instructions. This test was designed to detect CMV viral DNA in plasma (CMV viremia). Briefly, 50 μl of plasma was mixed with 500 μl of extraction reagent and were incubated at 100°C for 30 min, and 50 μl of the mixture was transferred into a PCR tube containing all the components necessary for PCR amplification plus an internal control (IC). The PCR tube was placed in the GeneAmp System 9600 (Perkin-Elmer) for PCR amplification. After amplification, the amplified nucleotide sequences were detected by an enzyme immunoassay technique. Absorbances were measured at 450 nm. Specimens having an absorbance value of ≥0.25 were considered positive, and values<0.25 were considered negative.
Fig. 1  CMV infection was investigated by attempting to detect CMV viremia with
the AMPLICOR™ CMV PCR test in 100 healthy volunteers whose IgG titer for
CMV was <4 and 100 healthy volunteers whose IgG titer for CMV was ≥4. The ab-
sorbances were measured at 450 nm. Positive, ≥0.25; negative, <0.25.

![Graph showing CMV infection in healthy volunteers](image)

Results

Cytomegalovirus detection in the plasma of healthy volunteers
It has been assumed that if CMV DNA is detected in a patient’s plasma, the patient can be diagnosed as having CMV infection. In other words, CMV is never detected in the plasma of a healthy person. Although this would seem to be true, no evidence has ever been published to corroborate it. We therefore tried to confirm the validity of this conclusion by using the AMPLICOR™ CMV test. We investigated whether it would be possible to detect CMV in the plasma of healthy volunteers. Two different subject groups were established: [1] healthy volunteers who had never been infected by CMV (IgG titer for CMV <4) and [2] healthy volunteers who had been already infected by CMV (IgG titer for CMV ≥4) (Fig. 1). Neither of the two groups included any persons who exhibited CMV viremia in their plasma (Fig. 1). These findings suggest that CMV cannot be detected in the plasma of healthy humans. Thus, if CMV DNA is detected in a patient’s plasma, the patient can be diagnosed as having CMV infection.

Cytomegalovirus detection in the plasma of immunocompromised patients

We attempted to identify the underlying conditions that facilitate CMV infection (Fig. 2). Only one patient in the benign disease category had CMV viremia; but all of the others were negative for CMV infection. None of the patients in the hematopoietic malignancy category had CMV infection; the patients in this group had never undergone bone marrow transplantation. Twenty-eight patients in the post-bone-marrow transplantation category were positive for CMV viremia, and 19 patients were positive in the post-renal transplantation category. The non-parametric Kruskal-Wallis test was applied to these results (Fig. 2), and a statistically significant difference in positivity for CMV viremia was found among these four categories (p<0.0001). Based on these findings, we conclude that CMV infection tends to occur in post-transplantation status and that it does not tend to occur in patients with hematopoietic malignancy if they have not undergone transplantation.

Discussion

Why does CMV infection tend to occur only in post-transplantation status? An immunosuppressant or a glucocorticoid therapy inhibits a patient’s immune system and facilitates proliferation of CMV in the immunocompromised patients of post-transplantation status. However, many patients in the benign disease category such as patients with collagen-vascular disease received such treatment, but did not show any evidence of CMV infection (Fig. 2).

Bone marrow transplantation, patients undergo whole-body irradiation, which completely destroys the patient’s immune system including the T-cell system. Although patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) were not evaluated in this study, they are known to be susceptible to CMV viremia when their CD4 count falls below than 50/μl, and thus a weakened host T-cell immune system might be associated with CMV infection.

One patient in the benign disease category was positive for CMV infection. The patient’s attending physician was unable to diagnose the underlying disease, but, at least, the patient did not have HIV/AIDS or malignant tumor.

According to our results, CMV infection seldom occurs in patients with benign disease or hematopoietic malignancy, even when their condition appears to be serious. Although this must be confirmed in a larger scale study in the future, this finding may be helpful to all physicians caring for patients suspected of having CMV infection or CMV disease.

References

2) Goulan J, Laporte JP, Lesage S et al.: Monitoring of cytomegalovirus infection and disease in bone marrow recipients by

平成11年2月20日


どんな基礎疾患がサイトメガロウイルス感染を引き起こしやすいか？

初めての標準化された客観的サイトメガロウイルス用 PCR キットを使用した。

良性疾患、血液恶性腫瘍、骨髄恶性腫瘍、骨髄移植後、腎移植後における比較

大阪市立大学医学部臨床検査医学教室

日吉 基文 田川 進一 橋本 卯巳 言 典之

要 旨

幼児、老人、癌患者、免疫抑制剤を投与されている患者など、あらゆる種類の日和見感染症主は活動性サイトメガロウイルス（CMV）感染などCMV 感染症に容易に罹患する傾向があると言われている。我々はこのことが実際であるかどうか疑問を持ち、世界初の標準化された CMV 感染症診断用の PCR キットであるアンプリコア CMV テスト（Roche Diagnostics Systems, Branchburg, NJ）を使って対象人の血漿中の CMV ウイルス血症を検出することにより、この事柄を調べた。CMV IgG 抗体価 4 未満の健常人 100 人と CMV-IgG 抗体価 4 以上の健常人 100 人が調べられた。両方の健常人グループには CMV ウイルス血症陽性は見つけられなかった。また CMV 感染が疑われられた患者は 4 つのグループに分けて調べられた。

(1) 104 人の良性疾患の患者群は 1 人の CMV ウイルス血症陽性を含んでいた。しかし他の患者はすべて陰性であった。(2) 骨髄移植を受けたことのない 99 人の血液悪性腫瘍はすべて CMV ウイルス血症陰性だった。(3) 骨髄移植後の 120 人の患者群は 28 人の CMV ウイルス血症陰性を含んでいた。4)) 骨髄移植後の 37 人の患者群は 19 人の CMV ウイルス血症陰性を含んでいた。これら 4 つの疾患グループ間で CMV ウイルス陽性率の統計学的有意差がノンパラメトリックテストの一つであるクルスカル・ワリステストによって見出された (p<0.0001)。今日まで、CMV 感染はあらゆるタイプの日和見患者に起こると言われてきた。しかしながら、実は CMV 感染は臓器移植後の状態に際りやすい傾向があり、移植を受けていない血液悪性腫瘍患者には起こりにくい傾向があるということを我々はこれらのデータにもとづき結論する。

感染症学雑誌 第73巻 第2号